Efficacy and Safety of Inetetamab Combined With Pyrotinib and Vinorelbine in ABC — HER2-VIP  

HER2-positive Advanced Breast Cancer Clinical Trial

Official title: Efficacy and Safety of Inetetamab Combined With Pyrotinib and Vinorelbine in the Treatment of Advanced Breast Cancer

Status Recruiting

Clinical Trial Summary

This is a prospective, no interventional, single arm cohort study, which aims to study the efficacy and safety of inetetamab combined with pyrotinib and vinorelbine in the Treatment of HER2 positive advanced breast cancer in the real world. The study will be conducted by signing an informed consent form for study enrollment, collecting patient case information, and conducting observation and follow-up.

Clinical Trial Description

This is a prospective, no interventional, single arm cohort study, which aims to study the efficacy and safety of inetetamab combined with pyrotinib and vinorelbine in the Treatment of HER2 positive advanced breast cancer in the real world. The study will be conducted by signing an informed consent form for study enrollment, collecting patient case information, and conducting observation and follow-up.The research process is divided into screening period, treatment period, and survival and follow-up periods. ;

Related Conditions & MeSH terms

• Breast Neoplasms
• HER2-positive Advanced Breast Cancer

• NCT number: NCT05856383
• Study type: Observational
• Source: Zhejiang Cancer Hospital
• Contact: Chen zhanhong
• Phone: +8613606505124
• Email: czred@sina.com
• Status: Recruiting
• Start date: March 16, 2022
• Completion date: December 31, 2027